Insider Selling: Krystal Biotech (NASDAQ:KRYS) Insider Sells $8,983,000.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. This represents a 1.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Trading Down 3.6%

Krystal Biotech stock traded down $13.23 during trading on Friday, hitting $358.24. 323,012 shares of the company were exchanged, compared to its average volume of 204,795. The business’s 50 day moving average is $349.81 and its 200 day moving average is $307.38. Krystal Biotech, Inc. has a 52 week low of $136.73 and a 52 week high of $382.54. The company has a market capitalization of $10.60 billion, a P/E ratio of 44.89 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Equities analysts expect that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

Institutional Trading of Krystal Biotech

Hedge funds have recently added to or reduced their stakes in the stock. Silvant Capital Management LLC bought a new position in shares of Krystal Biotech during the 2nd quarter valued at approximately $30,000. Western Wealth Management LLC purchased a new stake in shares of Krystal Biotech during the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC bought a new stake in shares of Krystal Biotech in the 4th quarter worth approximately $34,000. Danske Bank A S bought a new stake in shares of Krystal Biotech in the 3rd quarter worth approximately $35,000. Finally, UMB Bank n.a. lifted its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on KRYS shares. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Citigroup upped their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. HC Wainwright lifted their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Finally, Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.